studi
antibodi
respons
healthcar
worker
jeddah
saudi
arabia
surviv
middl
east
respiratori
syndrom
use
serial
elisa
indirect
immunofluoresc
assay
test
among
patient
experienc
sever
pneumonia
antibodi
detect
month
infect
antibodi
longev
variabl
patient
experienc
milder
diseas
studi
evalu
immun
respons
patient
infect
sever
acut
respiratori
syndrom
coronaviru
sarscov
show
antiviru
antibodi
survivor
detect
elisa
immunofluoresc
assay
ifa
month
infect
anoth
studi
reveal
sarscov
antibodi
detect
year
infect
antibodi
respons
middl
east
respiratori
syndrom
coronaviru
merscov
typic
detect
second
third
week
onset
infect
littl
known
longev
respons
whether
decreas
antibodi
respons
time
correl
sever
initi
infect
conduct
longitudin
studi
antibodi
respons
among
cohort
mer
survivor
treat
king
faisal
specialist
hospit
research
center
jeddah
saudi
arabia
kfshrcj
research
propos
approv
kfshrcj
institut
review
board
written
inform
consent
obtain
studi
particip
jeddah
mer
outbreak
test
specimen
patient
suspect
merscov
infect
use
realtim
revers
transcript
pcr
rrtpcr
assay
identifi
confirm
case
basi
rrtpcrposit
specimen
obtain
nasopharyng
swab
bronchoalveolar
lavag
describ
previous
onlin
technic
appendix
http
patient
specimen
analyz
rrtpcr
conduct
twice
eighteen
case
healthcar
worker
hcw
hcw
symptomat
asymptomat
hcw
identifi
contact
trace
activ
hospit
surveil
mer
case
patient
cohort
studi
consist
hcw
merscovposit
basi
rrtpcr
result
agre
provid
blood
sampl
serial
serolog
test
merscov
elisa
ifa
patient
medic
record
review
inform
demograph
characterist
comorbid
clinic
present
intens
care
unit
admiss
outcom
patient
classifi
categori
accord
clinic
present
asymptomat
upper
respiratori
tract
infect
pneumonia
sever
pneumonia
patient
sever
pneumonia
requir
intub
ventilatori
support
treat
intens
care
unit
serial
elisa
ifa
test
perform
month
ill
onset
onlin
technic
appendix
specimen
consid
repres
previou
infect
elisa
ifa
test
result
posit
microneutr
test
avail
kfshrcj
laboratori
diseas
onset
correspond
date
first
merscovposit
rrtpcr
result
data
avail
analysi
patient
merscovposit
serial
merscov
serolog
test
month
ill
onset
patient
sever
pneumonia
merscovantibodyposit
month
followup
test
month
serum
sampl
could
obtain
patient
also
merscovantibodyposit
month
patient
initi
healthi
without
underli
condit
except
patient
tabl
hypothyroid
four
patient
women
patient
week
week
pregnant
respect
merscov
infect
averag
patient
age
year
rang
year
patient
sever
pneumonia
milder
pneumonia
requir
intens
care
upper
respiratori
tract
diseas
remain
asymptomat
patient
recov
without
sequela
patient
sever
pneumonia
highest
antibodi
titer
detect
among
patient
remain
merscovantibodyposit
test
month
ill
onset
also
prolong
viral
shed
document
persist
posit
rrtpcr
result
day
patient
day
patient
rrtpcr
analys
neg
day
patient
rrtpcr
repeat
day
patient
result
neg
three
patient
pneumonia
merscovantibodyposit
month
antibodi
detect
month
tabl
patient
upper
respiratori
tract
function
remain
asymptomat
detect
antibodi
respons
basi
elisa
ifa
result
result
indic
longev
merscov
antibodi
respons
correl
diseas
sever
accordingli
patient
sever
mersassoci
pneumonia
persist
antibodi
respons
detect
month
infect
wherea
patient
diseas
confin
upper
respiratori
tract
clinic
sign
detect
merscov
antibodi
respons
two
previou
studi
describ
longitudin
analys
merscov
surfac
glycoproteinspecif
antibodi
respons
recov
patient
first
studi
describ
mer
outbreak
jordan
merscov
antibodi
includ
neutral
antibodi
still
detect
patient
pneumonia
month
infect
patient
sever
pneumonia
second
studi
drosten
et
al
demonstr
merscov
neutral
antibodi
produc
low
level
mild
subclin
infect
potenti
shortliv
result
studi
implic
understand
pathogenesi
treatment
mer
first
patient
mild
subclin
infect
detect
antibodi
respons
might
risk
recurr
infect
would
also
detect
populationbas
studi
result
fals
low
preval
rate
previou
studi
suggest
neutral
antibodi
suffici
clear
merscov
neutral
antibodi
detect
fatal
mer
case
antibodi
level
correl
well
viru
load
lung
tcell
respons
critic
protect
subsequ
challeng
anim
experiment
infect
sarscov
although
cell
persist
year
sar
survivor
whether
patient
would
protect
infect
second
time
sarscov
unknown
addit
studi
requir
assess
rel
import
tand
bcell
respons
mer
survivor
second
specul
patient
lowlevel
viru
replic
could
provid
reservoir
infect
highli
suscept
human
ie
underli
condit
patient
would
difficult
detect
transient
posit
merscov
antibodi
might
never
mount
antibodi
respons
merscov
third
patient
recov
sever
pneumonia
associ
mer
probabl
would
good
candid
provid
merscovspecif
convalescentphas
serum
sampl
use
treatment
trial
studi
limit
small
number
patient
number
lack
neutral
antibodi
test
elisa
highli
sensit
might
crossreact
season
human
coronaviru
antibodi
use
screen
test
sensit
ifa
ifa
requir
confirm
use
spike
proteinspecif
ifa
greatli
diminish
likelihood
crossreact
neutral
assay
consid
definit
must
perform
whenev
result
elisa
ifa
conclus
patient
report
elisa
ifa
result
consist
conclus
limit
studi
serolog
test
singl
patient
perform
day
therefor
qualit
quantit
conclus
chang
time
ill
onset
made
conclus
result
indic
merscov
antibodi
persist
depend
diseas
sever
studi
requir
determin
role
virusspecif
tcell
respons
mer
patient
determin
whether
patient
mild
infect
risk
reinfect
would
therefor
benefit
vaccin
data
also
show
potenti
donor
merscov
convalescentphas
serum
sampl
limit
patient
recov
sever
pneumonia
